S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:NBRV

Nabriva Therapeutics Stock Forecast, Price & News

$1.18
-0.03 (-2.48 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.16
$1.21
50-Day Range
$1.01
$1.22
52-Week Range
$1.00
$6.19
Volume487,415 shs
Average Volume2.40 million shs
Market Capitalization$586.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
30 days | 90 days | 365 days | Advanced Chart
Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Nabriva Therapeutics logo

About Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.04 out of 5 stars

Medical Sector

509th out of 1,351 stocks

Pharmaceutical Preparations Industry

248th out of 664 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

Is Nabriva Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Nabriva Therapeutics?

Wall Street analysts have given Nabriva Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nabriva Therapeutics?

Nabriva Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,540,000 shares, a drop of 31.3% from the August 15th total of 2,240,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is currently 1.3 days. Currently, 3.2% of the shares of the stock are short sold.
View Nabriva Therapeutics' Short Interest
.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Nabriva Therapeutics
.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company had revenue of $8.24 million for the quarter, compared to analyst estimates of $5.99 million. Nabriva Therapeutics had a negative net margin of 210.82% and a negative trailing twelve-month return on equity of 63.27%.
View Nabriva Therapeutics' earnings history
.

How has Nabriva Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NBRV stock has decreased by 2.5% and is now trading at $1.18.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBRV?

2 equities research analysts have issued 1 year price targets for Nabriva Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $6.00 in the next year. This suggests a possible upside of 408.5% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:
  • Theodore R. Schroeder, Chief Executive Officer & Director
  • Steven P. Gelone, President, Chief Operating Officer & Director
  • Dan Dolan, Chief Financial Officer
  • Kim Anderson, Investor Contact
  • Robert L. Crotty, Secretary & General Counsel

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.18%), State Street Corp (0.04%), Morgan Stanley (0.02%), Morgan Stanley (0.02%), Susquehanna International Group LLP (0.00%) and Parametric Portfolio Associates LLC (0.01%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Stephen W Webster and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics
.

Which institutional investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, and Citadel Advisors LLC.
View insider buying and selling activity for Nabriva Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Nabriva Therapeutics stock?

NBRV stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, State Street Corp, HAP Trading LLC, Millennium Management LLC, Parametric Portfolio Associates LLC, and Clear Creek Financial Management LLC.
View insider buying and selling activity for Nabriva Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.18.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics has a market capitalization of $586.92 million and generates $5.03 million in revenue each year. The biotechnology company earns $-69,480,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.

How many employees does Nabriva Therapeutics have?

Nabriva Therapeutics employs 72 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is www.nabriva.com.

Where are Nabriva Therapeutics' headquarters?

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.